Beta Drugs Share Price
NSE: BETA | Pharmaceuticals | Small Cap
Beta Drugs Annualised Returns
Beta Drugs Annualised Returns
Beta Drugs Share Price Today
Beta Drugs Share Price Today
As of 21 Oct 2026, Beta Drugs share price is ₹1664.7. The stock opened at ₹1701.1 and had closed at ₹1719.6 the previous day. During today’s trading session, Beta Drugs share price moved between ₹1,629.00 and ₹1,710.00, with an average price for the day of ₹1669.50. Over the last 52 weeks, the stock has recorded a low of ₹990.10 and a high of ₹2,807.90. In terms of performance, Beta Drugs share price has increased by 24.8% over the past six months and has declined by 0.7% over the last year.
Beta Drugs Stock Performance
Beta Drugs Share Price Chart
Beta Drugs Share Price Chart
Beta Drugs Company background
Beta Drugs Limited was incorporated as a private limited company with the name Beta Drugs Private limited at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to Beta Drugs Limited on August 11, 2017 Beta Drugs is a part of Adley Group. Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India. The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014. The company is primarily engaged in the manufacturing of oncology products. The Companys products range from anticancer tablets, capsules, injections and lyophilized injections. The Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease. The Company set up the first Oncology Unit in Adley Formulations Pvt Ltd. in 2008. It set up a new state of the art manufacturing facility for oncology formulations in 2014 developed inhouse Albumin bound Paclitaxel in 2015 started inhouse API Plant Adley Labs in 2017. In October, 2017, the Company came up with a Public Issue of 22,96,000 Equity Shares by raising equity capital aggregating Rs 19.5 Crores.The Company set up an Oncology Plant in Uzbekistan in 2018. In 2020, the Company launched GEMRTU, ADLEAP, ADLANTE, BEXINIB launched 1st Indian Brand of Dasatinib, BEEDAN. In 2025, the Company launched 1st Indian brand of Sunitinib, ADSUNIB.
Beta Drugs Financial Highlights
For Q1 FY2026–2027, Beta Drugs's revenue reached ₹127.13 crore and profit touched at ₹15.80 crore. As of 21 October 2026, Beta Drugs’s market capitalization reached at ₹1,845.47 crores. Shareholding as of 21 October 2026 shows promoters holding 58.9%, with FIIs at 1.4%, DIIs at 6.4%, and public at 33.3%.
Beta Drugs Fundamental
Market Cap (in crs)
1,845.47
Face Value
10
Turnover (in lacs)
415.81
Key Metrics
Beta Drugs Key Financials
View moreBeta Drugs Result Highlights
-
Beta Drugs reported a - quarter-on-quarter (QoQ) - in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
-
Its expenses for the quarter were - by - QoQ and - - YoY.
-
The net profit - - QoQ and - - YoY.
-
The earnings per share (EPS) of Beta Drugs stood at 8.4 during Q3 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Beta Drugs Technical Analysis
Delivery & Volume
Delivery Volume %
Day
46.90%
Week
40.90%
Month
44.20%
Resistance & Support
Beta Drugs Peer comparison
CompareIndex Name | Market Price |
|---|---|
1,513.80 -79.40 (-4.98%)▼ | |
2,170.30 -96.40 (-4.25%)▼ | |
22.07 +0.66 (+3.08%)▲ | |
2,623.40 -149.50 (-5.39%)▼ | |
1,365.90 -72.50 (-5.04%)▼ | |
881.30 -24.80 (-2.74%)▼ |
Beta Drugs Latest News
Beta Drugs Share Price FAQs
Beta Drugs share price in the past 1-year return was -8.55. The Beta Drugs share hit a 1-year low of Rs. 990.1 and a 1-year high of Rs. 2807.9.
The market cap of Beta Drugs is Rs. 1845.47 Cr. as of 21/10/2026.
The PE ratios of Beta Drugs is 115.12 as of 21/10/2026.
The PB ratios of Beta Drugs is 12.26 as of 21/10/2026
You can easily buy Beta Drugs shares in Kotak Neo by opening a demat account and getting the KYC documents verified online.
The 52-week high and low of Beta Drugs share price is ₹2807.9 and ₹990.1 as of 21/10/2026.
Please be aware that Beta Drugs stock prices are subject to continuous fluctuations due to various factors.